Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Hepatic Impairment

Interventions

DRUG

Sativex

Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.

Trial Locations (2)

Anaheim Clinical Trials, LLC, Anaheim

Clinical Pharmacology of Miami, Inc., Miami